Gilead Sciences (GILD) Stock Price, Fundamentals & Analysis
Price
151.37 USD
-0.85%
Price history
Over the past year GILD traded between 110.56 USD and 155.8 USD, closing at 151.37 USD on Sep 24, 2026.
Key statistics
| Market cap | 187.69B USD |
|---|---|
| Forward P/E | 15.3 |
| EPS (TTM) | -2.66 USD |
| Dividend yield | 2.15% |
| Annual dividend | 3.28 USD |
| Ex-dividend date | Sep 15, 2026 |
| Payout ratio | 43% |
| 52-week range | 108.46 – 157.29 |
| 52-week change | 34.3% |
| Beta | 0.35 |
| Price / book | 15.88 |
| Revenue (TTM) | 30.46B USD |
| Revenue growth (YoY) | 10.2% |
| Gross margin | 79.6% |
| Operating margin | 33.7% |
| Profit margin | -10.6% |
| Return on equity | -20.7% |
| Debt / equity | 223.5 |
| Volume | 5,803,574 |
| Average volume | 6,661,682 |
| Next earnings | Oct 29, 2026 |
| Exchange | NasdaqGS |
Profile
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 17,000
- Headquarters
- Foster City, United States
- Website
- gilead.com
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases.
Overview
What GILD does
Gilead Sciences (GILD) is a biopharmaceutical company that discovers, develops, and commercialises medicines in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo for the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases.
Key numbers explained
- 151.37 USD is the current share price, representing the latest trading value of one share.
- 187.69B USD is the market capitalisation, the total value of all outstanding shares; it places the company among the largest in the S&P 500.
- 15.3 is the forward P/E ratio, which divides the share price by expected future earnings and is used to compare valuation across peers like Pfizer (PFE).
- -2.66 USD is the earnings per share for the trailing 12 months, showing the net loss per share over that period.
- 2.15% is the dividend yield, the annual dividend payment expressed as a percentage of the share price.
- 108.46 – 157.29 is the 52-week price range, showing the lowest and highest traded prices over the past year.
- 0.35 is beta, a measure of volatility relative to the market; a value below 1 suggests lower sensitivity to market swings.
- 223.5% is the debt-to-equity ratio, comparing total debt to shareholders' equity and indicating the company's financial leverage.
Recent news
Recent headlines cover a 1.40% move in the stock and its inclusion on a list of cash-producing stocks alongside risk assessments. Other stories compare Gilead Sciences (GILD) with Bristol-Myers Squibb (BMY) and discuss Morgan Stanley's positive view on the company's HIV prevention strategy. Additional coverage highlights efforts to widen access to lenacapavir across 120 countries.
What to watch
Investors typically monitor product performance in HIV and oncology, pipeline progress in immunotherapies, and regulatory developments in the United States and Europe. Broader factors include healthcare policy changes, pricing pressures, and competition within the drug manufacturing sector.
What GILD does
Key numbers explained
Recent news
What to watch
Latest news & filings
- Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know
Zacks · Sep 22, 2026
- 1 Cash-Producing Stock on Our Buy List and 2 We Find Risky
StockStory · Sep 22, 2026
- BMY vs GILD: Which Biotech Stock Looks More Attractive Now?
Zacks · Sep 21, 2026
- Novo Nordisk Stock Drops 5.6% as 2030 Goals Match Peers
GuruFocus.com · Sep 21, 2026
- Why Morgan Stanley likes Gilead's HIV prevention play
TheStreet · Sep 20, 2026
- Why Is Gilead Sciences (GILD) Widening Lenacapavir Access Across 120 Countries?
Simply Wall St. · Sep 20, 2026
- Gilead Strengthens HIV Growth Platform with Expanded Latin America Access
Insider Monkey · Sep 18, 2026
- 4 Biotech Stocks to Watch as Potential Takeover Targets
Zacks · Sep 18, 2026
- J&J Up 18% in Three Months: Buy, Sell or Hold the Stock?
Zacks · Sep 18, 2026
- Latin America’s PAHO-Gilead HIV Prevention Deal Is a Victory for Civil Society, says AHF
Business Wire · Sep 17, 2026
Frequently asked questions
Does GILD pay a dividend?
Yes, Gilead Sciences (GILD) pays a dividend with a yield of 2.15%. The ex-dividend date is Sep 15, 2026, and 43% of earnings are paid out as dividends.
What is the GILD P/E ratio?
The forward P/E ratio is 15.3, based on expected earnings. This is a common way to assess how the market values the company relative to its anticipated profit.
Where can I buy GILD?
Gilead Sciences (GILD) trades on the US market as a stock. You can buy it through any broker that offers access to US equities.
What does GILD do?
Gilead Sciences (GILD) discovers, develops, and commercialises medicines for HIV-1, hepatitis B and C, cancer, and other serious diseases, including CAR T-cell therapies and antifungal treatments.
Is GILD profitable?
The trailing 12-month earnings per share is -2.66 USD, and the profit margin is -10.6%, indicating a net loss over that period despite positive operating margins.
How volatile is GILD compared to the market?
With a beta of 0.35, Gilead Sciences (GILD) tends to be less volatile than the overall market, suggesting smaller price swings relative to broad market movements.
Related
More on GILD
Track GILD in your portfolio
Hold GILD at XTB, IBKR, Tradeville, Revolut or Trading 212? InvestPane brings every broker into one dashboard — allocation, performance and dividends in one place.
Start free